Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fluciclovine PET for malignant brain tumors
jRCT1061240127Phase 2Recruiting
- Start
- Jun 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclovine f 18 in high-grade glioma (HGG), brain neoplasm and primary central nervous system lymphoma (PCNSL). Primary endpoint: Correlation of fluciclovine PET uptake with histological findings. Started Jun 2025; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
high-grade glioma (HGG)brain neoplasmprimary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on jRCT1061240127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061240127.